FDA advisory panel suggests regular bivalent COVID immunization
JHVEPhoto


A panel of advisors to the US FDA has suggested that individuals get COVID-19 updated shots on a regular basis to keep up with new variants.
The Vaccines and Related Vaccines Biological Products Advisory Committee agreed that additional information on how the vaccines are working in the population, as well as T-cell and antibody responses, are needed in the future.

Peter Marks, director of the FDA's director of the Center for Biologics Evaluation and Research, said that meetings to discuss the composition of COVID vaccines should be held at least once a year. He added that a meeting should be held in late May or early June to help vaccine makers manufacture their shots in time for the fall.
Representatives from Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX) made presentations.
Earlier Thursday, the FDA it did not find an increased stroke risk in seniors who received the updated Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID shot.